What is Tagrisso?

Category: Prescription Drugs

true

Generic name: Osimertinib

Tagrisso™ (osimertinib) is intended for the treatment of advanced non-small cell lung cancer in patients with a specific EGFR mutation. 

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 1
Mild 2
None 0

Commonly reported side effects and conditions associated with Tagrisso

Side effect Patients
Brittle hair 1
Broken nails 1
Decreased appetite 1
Diarrhea 1
Dizziness 1
Dry lips 1

Show all 9 reported side effects

Dosages

Based on patients currently taking Tagrisso

Dosage Patients
80 mg daily 8

Why patients stopped taking Tagrisso

Multiple reasons could be selected

Reason Patients
Did not seem to work 2
Doctor's advice 1
See all 2 patients who've stopped taking Tagrisso

Duration

Currently taking Tagrisso

Duration Patients
1 - 6 months 2
6 months - 1 year 4
1 - 2 years 2

Stopped taking Tagrisso

Duration Patients
1 - 6 months 1
1 - 2 years 1
Adherence
Adherence Evaluations
Always 3
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 2
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 2
$25-49 0
< $25 1
Not specified 0

What people switch to and from

Patients started taking Tagrisso after stopping:

Treatment Patients
Erlotinib (Tarceva) 6
Chemotherapy 4
Afatinib (Gilotrif) 1
Gefitinib (Iressa) 1

Patients stopped taking Tagrisso and switched to:

Treatment Patients
Chemotherapy 2
Pembrolizumab (Keytruda) 1
Last updated:
There are no evaluations for Tagrisso.